BACKGROUND: No prospective studies are available on serum cotinine level as a marker of lung cancer risk. METHODS: We analyzed serum cotinine level among 1,741 individuals enrolled since the 1970s in a prospective study of Norwegian volunteers who developed lung cancer during the follow-up and 1,741 matched controls free from lung cancer. Serum cotinine was measured with a competitive immunoassay. Regression dilution was corrected for based on repeated measures on samples from 747 subjects. RESULTS: Mean serum cotinine level was higher in cases than in controls. Compared with subjects with a cotinine level of < or = 5 ng/mL, the odds ratio of lung cancer was increasing linearly, reaching 55.1 (95% confidence interval, 35.7-85.0) among individuals with a serum cotinine level of > 378 ng/mL. There was no clear suggestion of a plateau in risk at high exposure levels. Odds ratios were very similar in men and women. We found no association between serum cotinine level (range, 0.1-9.9 ng/mL) and lung cancer risk among self-reported nonsmokers and long-term quitters (79 cases and 350 controls). DISCUSSION: The association between tobacco smoking and lung cancer risk might be stronger than is estimated from questionnaire-based studies. Serum cotinine level is a predictor of risk of lung cancer among smokers. The reported plateau in risk at high doses is likely due mainly to artifacts. There is no difference between men and women in the carcinogenicity of tobacco smoking.
BACKGROUND: No prospective studies are available on serum cotinine level as a marker of lung cancer risk. METHODS: We analyzed serum cotinine level among 1,741 individuals enrolled since the 1970s in a prospective study of Norwegian volunteers who developed lung cancer during the follow-up and 1,741 matched controls free from lung cancer. Serum cotinine was measured with a competitive immunoassay. Regression dilution was corrected for based on repeated measures on samples from 747 subjects. RESULTS: Mean serum cotinine level was higher in cases than in controls. Compared with subjects with a cotinine level of < or = 5 ng/mL, the odds ratio of lung cancer was increasing linearly, reaching 55.1 (95% confidence interval, 35.7-85.0) among individuals with a serum cotinine level of > 378 ng/mL. There was no clear suggestion of a plateau in risk at high exposure levels. Odds ratios were very similar in men and women. We found no association between serum cotinine level (range, 0.1-9.9 ng/mL) and lung cancer risk among self-reported nonsmokers and long-term quitters (79 cases and 350 controls). DISCUSSION: The association between tobacco smoking and lung cancer risk might be stronger than is estimated from questionnaire-based studies. Serum cotinine level is a predictor of risk of lung cancer among smokers. The reported plateau in risk at high doses is likely due mainly to artifacts. There is no difference between men and women in the carcinogenicity of tobacco smoking.
Authors: Jeannette Zinggeler Berg; Linda B von Weymarn; Elizabeth A Thompson; Katherine M Wickham; Natalie A Weisensel; Dorothy K Hatsukami; Sharon E Murphy Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-05-25 Impact factor: 4.254
Authors: Mariah M Marshall; Gregory D Kirk; Neil E Caporaso; Meredith C McCormack; Christian A Merlo; John C Hague; Shruti H Mehta; Eric A Engels Journal: Addict Behav Date: 2010-09-26 Impact factor: 3.913
Authors: Jelle Vlaanderen; Lützen Portengen; Joachim Schüz; Ann Olsson; Beate Pesch; Benjamin Kendzia; Isabelle Stücker; Florence Guida; Irene Brüske; Heinz-Erich Wichmann; Dario Consonni; Maria Teresa Landi; Neil Caporaso; Jack Siemiatycki; Franco Merletti; Dario Mirabelli; Lorenzo Richiardi; Per Gustavsson; Nils Plato; Karl-Heinz Jöckel; Wolfgang Ahrens; Hermann Pohlabeln; Adonina Tardón; David Zaridze; John K Field; Andrea 't Mannetje; Neil Pearce; John McLaughlin; Paul Demers; Neonila Szeszenia-Dabrowska; Jolanta Lissowska; Peter Rudnai; Eleonora Fabianova; Rodica Stanescu Dumitru; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Paolo Boffetta; Francesco Forastiere; Bas Bueno-de-Mesquita; Susan Peters; Thomas Brüning; Hans Kromhout; Kurt Straif; Roel Vermeulen Journal: Am J Epidemiol Date: 2013-12-18 Impact factor: 4.897
Authors: Jonathan M Samet; Erika Avila-Tang; Paolo Boffetta; Lindsay M Hannan; Susan Olivo-Marston; Michael J Thun; Charles M Rudin Journal: Clin Cancer Res Date: 2009-09-15 Impact factor: 12.531
Authors: Beate Pesch; Benjamin Kendzia; Per Gustavsson; Karl-Heinz Jöckel; Georg Johnen; Hermann Pohlabeln; Ann Olsson; Wolfgang Ahrens; Isabelle Mercedes Gross; Irene Brüske; Heinz-Erich Wichmann; Franco Merletti; Lorenzo Richiardi; Lorenzo Simonato; Cristina Fortes; Jack Siemiatycki; Marie-Elise Parent; Dario Consonni; Maria Teresa Landi; Neil Caporaso; David Zaridze; Adrian Cassidy; Neonila Szeszenia-Dabrowska; Peter Rudnai; Jolanta Lissowska; Isabelle Stücker; Eleonora Fabianova; Rodica Stanescu Dumitru; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Charles M Rudin; Paul Brennan; Paolo Boffetta; Kurt Straif; Thomas Brüning Journal: Int J Cancer Date: 2011-12-14 Impact factor: 7.396
Authors: Tricia L Larose; Florence Guida; Anouar Fanidi; Arnulf Langhammer; Kristian Kveem; Victoria L Stevens; Eric J Jacobs; Stephanie A Smith-Warner; Edward Giovannucci; Demetrius Albanes; Stephanie J Weinstein; Neal D Freedman; Ross Prentice; Mary Pettinger; Cynthia A Thomson; Qiuyin Cai; Jie Wu; William J Blot; Alan A Arslan; Anne Zeleniuch-Jacquotte; Loic Le Marchand; Lynne R Wilkens; Christopher A Haiman; Xuehong Zhang; Meir J Stampfer; Allison M Hodge; Graham G Giles; Gianluca Severi; Mikael Johansson; Kjell Grankvist; Renwei Wang; Jian-Min Yuan; Yu-Tang Gao; Woon-Puay Koh; Xiao-Ou Shu; Wei Zheng; Yong-Bing Xiang; Honglan Li; Qing Lan; Kala Visvanathan; Judith Hoffman Bolton; Per Magne Ueland; Øivind Midttun; Neil Caporaso; Mark Purdue; Howard D Sesso; Julie E Buring; I-Min Lee; J Michael Gaziano; Jonas Manjer; Hans Brunnström; Paul Brennan; Mattias Johansson Journal: Int J Epidemiol Date: 2018-12-01 Impact factor: 7.196